Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Respiratory Syncytial Virus Infections (3 trials)
- Main trialPhase 2
- “This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.”In the company’s words, NCT02094365 on ClinicalTrials.gov
Other drugs for Respiratory Syncytial Virus Infections
- RSVPreF3 OA vaccineGSK · Phase 3
- Human interferon α1b InhalationKexing Biopharm Co., Ltd. · Phase 3
- ABRYSVOPfizer · Phase 3
- ZiresovirShanghai Ark Biopharmaceutical Co., Ltd. · Phase 2/3
- S-337395Shionogi · Phase 2
- ZelicapavirEnanta Pharmaceuticals, Inc · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | Jun 2014 | A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model | |
| Phase 2Completed | 31 Oct 2016 | A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus | |
| Phase 1Completed | 15 Feb 2018 | A Study of ALS-008176 in Infants Hospitalized With RSV |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026